Boston Scientific price target raised to $110 from $100 at Mizuho

Mizuho raised the firm’s price target on Boston Scientific (BSX) to $110 from $100 and keeps an Outperform rating on the shares post the Q3 report. The AVANT Guard trial setback is not linked to a mortality event or initiated by FDA and global Farapulse momentum is sustainable over the medium-term, the analyst tells investors in a research note. The firm believes the pullback in Boston Scientific shares presents a “compelling” entry point.